Exelon helps Alzheimer's disease patients to maintain greater independence

April 03, 2003 01:30 ET | Source: Novartis Pharma AG Novartis Pharma AG

Exelon® helps Alzheimer's disease patients to maintain greater independence

New findings suggest Exelon® significantly reduces decline in performance of activities of daily living in moderate to moderately severe Alzheimer's disease

Basel, 3 April 2003 - Therapy with Exelon (rivastigmine) helps patients with moderate to moderately severe Alzheimer's disease (AD) to maintain greater independence, according to an analysis of nearly 1500 patients.

Please find press release under the following link

Attachments

Media Release...

Recommended Reading

March 06, 2026 08:24 ET | Source: Novartis Pharma AG

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as...
Read More
February 27, 2026 09:00 ET | Source: Novartis Pharma AG

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks...
Read More